AMRI Files Motion for Preliminary Injunction Prohibiting Dr. Reddy's from Distributing Generic Allegra-D® 24
Albany, NY (March 23, 2010)-AMRI (NASDAQ: AMRI) today announced that it along with sanofi-aventis U.S. LLC, has filed a motion for a preliminary injunction in the United States District Court for the District of New Jersey seeking to enjoin Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc. (Dr. Reddy's) from the commercial distribution of generic versions of Allegra-D® 24 Hour (fexofenadine HCl 180 mg and pseudoephedrine HCl 240 mg) Extended-Release Tablets in the U.S. This action is in response to the March 17, 2010 approval of Dr. Reddy's generic version of Allegra-D® 24 Hour by the FDA.
In September 2009, AMRI filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Dr. Reddy's for infringement of one of AMRI's patents related to the manufacturing process for the active ingredient in Allegra® , Allegra-D® 12, and Allegra-D® 24 Hour, which issued in 2008. Sanofi-aventis U.S. is now joining AMRI in this lawsuit.
Regardless of the outcome of the preliminary injunction motion, AMRI will continue to forcefully and vigorously defend its intellectual property.
Founded in 1991, Albany Molecular Research, Inc. (AMRI) provides scientific services, products and technologies focused on improving the quality of life. AMRI works on drug discovery and development projects and conducts manufacturing of active ingredients and pharmaceutical intermediates for many of the world's leading healthcare companies. As an additional value added service to its customers, the company is also investing in R&D in order to expand its contract services and to identify novel early stage drug candidates with the goal to outlicense to a strategic partner. With locations in the U.S., Europe, and Asia, AMRI provides customers with a wide range of services, technologies and cost models.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements may be identified by forward-looking words such as "may," "could," "should," "would," "will," "intend," "expect," "anticipate," "believe" and "continue" or similar words. Readers should not place undue reliance on our forward-looking statements. The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not be within the company's control. Factors that could cause such differences include, but are not limited to the company's ability to attract and retain experienced scientists, trends in pharmaceutical and biotechnology companies outsourcing of chemical research and development, the company's ability to enforce its intellectual property and technology rights, the risks posed by international operations to the company, and the company's ability to effectively manage its growth as well as those factors discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2009 as filed with the Securities and Exchange Commission on March 12, 2010 and the company's other SEC filings. The company does not undertake any duty to and does not intend to update any forward-looking statements contained in this press release after the date of this press release.
Media - Andrea Schulz, Director, Corporate Communications, 518-512-2226
Investors - Peter Jerome, Director, Investor Relations, 518-512-2220